Bausch Health expects to raise full-year 2026 adjusted EBITDA guidance
BHC•Bausch Health expects to raise its full-year 2026 adjusted EBITDA guidance, excluding acquired IPR&D, based on preliminary third-quarter results and stronger expected business performance for the rest of the year, supported by prevailing foreign exchange rates.
1. Guidance update
Bausch Health said it expects to raise its full-year 2026 adjusted EBITDA guidance, excluding acquired IPR&D, based on preliminary third-quarter results. The company cited stronger expected business performance for the rest of 2026, supported by prevailing foreign exchange rates. It also reported 13 consecutive quarters of year-over-year revenue and adjusted EBITDA growth, excluding Bausch + Lomb. More details are expected with third-quarter results on Oct. 28.
